Evidence map›Paper›PMID 34926667›Full record

ArticleAnnals of translational medicine2021

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).

Zhenyang Zhang, Zhi-Nuan Hong, Shuhan Xie, Wenwei Lin, Yukang Lin, Jiafu Zhu, Xiaojie Yang, Zhiwei Lin, Jiangbo Lin, Mingqiang Kang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 7 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 7 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Survival benefit and dynamics of CD8Frontiers in immunology · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhenyang Zhang *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhi-Nuan Hong *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Shuhan Xie *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Wenwei LinDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Yukang LinFujian Medical University, Fuzhou, China.
Jiafu ZhuDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Xiaojie YangDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhiwei LinDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Jiangbo Lin *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Mingqiang Kang *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Fujian Medical University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the safety and feasibility of combining neoadjuvant sintilimab (Innovent Biologics, Suzhou, China) and chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).

methodsThe study was an investigator-initiated, open-label, non-randomized, single-arm, single-center phase 2 trial. Patients aged between 18 to 75 years with locally advanced ESCC were eligible for neoadjuvant immunochemotherapy (nICT). The nICT included cisplatin (60 mg/m

resultsFrom July 2020 to June 2021, 30 patients were enrolled. All patients successfully completed 2 cycles of nICT. AEs were common during nICT, and the most common AE was anorexia (20/30, 67%). However, only one patient with grade 3 ESCC had increased transaminase. According to radiologic evaluations, the objective response rate (ORR) was 67% (20/30) and the disease control rate 97% (29/30). Twenty-three patients underwent McKeown minimally invasive esophagectomy (MIE). The pCR rate of the primary tumor was 21.7%, and the MPR rate of the primary tumor was 52.2%. The median interval to surgery was 40 days, and no patients delayed surgery due to AEs. Pneumonia was the most common major 30-day postoperative complication (9/23, 39%). Anastomotic leakage (AL) occurred in two patients during the hospital stay, and one patient was readmitted due to AL. There was no treatment- or surgery-related deaths.

conclusionsNeoadjuvant sintilimab plus chemotherapy for locally advanced ESCC appears to be safe and feasible with limited AEs, high R0 resection rate, promising pCR rate, and manageable postoperative complications. Long-term follow-up is required. A multicenter, randomized, phase III clinical trial assessing the efficacy and safety of sintilimab versus placebo in combination with chemotherapy in locally advanced ESCC is warranted to confirm these results.

Indexed as

clinical trialEsophageal squamous cell carcinoma (ESCC)neoadjuvant immunochemotherapy (nICT)phase II

Identifiers

PMID34926667
PMCPMC8640906
OpenAlexW3211999657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.